Key facts
- It has raised $55.6M; the latest was Secondary Transaction - Private in Oct 2025.
- Notable investors include Oriental Fortune Capital, Zizhu Xiaomiao PE, Gopher Asset Management, Ancheng Capital, China Resources Capital Management — 14 tracked in total.
- Status: Privately Held (backing).
Investors
14+- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for BRL Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for BRL Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BRL Medicine
Developer of gene editing and cell engineering platforms intended for genetic and immune-related disorders. The company offers an integrated technology ecosystem that includes hematopoietic stem cell modification, universal immune cell engineering, non-viral CAR-T integration, enhanced T-cell development, and in vivo gene editing capabilities, enabling research institutions and clinical developers to create precise, adaptable treatments that improve therapeutic outcomes and support next-generation regenerative medicine.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2013
- Employees
- 153
- Website
- brlmed.com/
- Ownership
- Privately Held (backing)
BRL Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BRL Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BRL Medicine in its N-PORT filings yet. We sweep new filings monthly.